Management of Malaria
For uncomplicated P. falciparum malaria, treat with artemisinin-based combination therapy (ACT), specifically artemether-lumefantrine or dihydroartemisinin-piperaquine as first-line agents; for severe malaria, immediately initiate intravenous artesunate regardless of trimester in pregnancy. 1
Uncomplicated Plasmodium falciparum Malaria
First-Line Treatment
Artemisinin-based combination therapies (ACTs) are the definitive first-line treatment for uncomplicated P. falciparum malaria. 1 These regimens provide rapid parasite clearance, reduce hospital stay, and demonstrate superior safety profiles compared to older antimalarials. 1
Preferred ACT regimens:
Artemether-lumefantrine (AL): 4 tablets at hours 0,8,24,36,48, and 60 (total 24 tablets over 72 hours) for patients >35 kg. Must be taken with fatty food or drink to enhance absorption. 1
Dihydroartemisinin-piperaquine: 3 tablets daily for 3 days (36-75 kg) or 4 tablets daily for 3 days (>75 kg). Must be taken on an empty stomach. 1
Critical caveat: Avoid both ACTs in patients with QTc prolongation risk or those taking QTc-prolonging medications. 1
Second-Line Treatment
Atovaquone-proguanil is the preferred alternative when ACTs are contraindicated: 4 tablets daily for 3 days (>40 kg) with fatty food. 1 This regimen is slower-acting but well-tolerated, with primarily gastrointestinal side effects. 1
Geographic Resistance Considerations
For infections acquired in Southeast Asia (especially Greater Mekong sub-region), avoid ACTs due to established artemisinin resistance. 1 Use atovaquone-proguanil as first-line in these cases. 1
Admission Criteria
Most patients with P. falciparum malaria require hospital admission for at least 24 hours due to risk of sudden deterioration. 2 Outpatient treatment may be considered only in specialized centers with established protocols for patient selection and close follow-up. 1, 2
Severe Malaria
Diagnostic Criteria
Severe malaria is defined by any of the following: 1
- Neurological: Unarousable coma, multiple convulsions
- Cardiovascular/Respiratory: Shock, pulmonary edema, ARDS
- Renal: Urine output <400 mL/24 hours, creatinine >3 mg/dL
- Hematologic: Hemoglobin <7 g/dL
- Metabolic: Glucose <40 mg/dL, acidosis
- Hepatic: Jaundice with parasitemia >100,000/mL
- Parasitemia: >5% in non-immune individuals (threshold varies 2-5% across guidelines) 1
Treatment
Intravenous artesunate is the definitive first-line treatment for severe malaria in all patients, including pregnant women in any trimester. 1, 2 This represents the highest quality evidence, with artesunate demonstrating faster parasite clearance and shorter ICU stays compared to quinine. 1
If artesunate is unavailable, immediately initiate intravenous quinine while arranging artesunate transfer. 2 Do not delay treatment waiting for artesunate if quinine is immediately available. 2
Critical management points:
- Manage in ICU or high-dependency unit 2
- Monitor for hypoglycemia (especially with quinine) 2
- Treat children empirically with broad-spectrum antibiotics until bacterial infection excluded 2
- Check hemoglobin at day 14 post-treatment, as 10-15% develop delayed hemolysis after intravenous artesunate 2
Malaria in Pregnancy
Uncomplicated Malaria
For second and third trimester uncomplicated P. falciparum malaria, artemether-lumefantrine is the treatment of choice. 1 Both WHO and CDC now endorse AL use in all trimesters based on strong safety and efficacy evidence. 1
For first trimester uncomplicated malaria, artemether-lumefantrine is recommended when other options are unavailable; otherwise use quinine plus clindamycin. 1 The evidence now supports AL safety throughout pregnancy, though some guidelines remain conservative for first trimester. 1
Dosing: Standard artemether-lumefantrine regimen (4 tablets at 0,8,24,36,48,60 hours) with fatty food. 1
Severe Malaria in Pregnancy
Intravenous artesunate is preferred over quinine for severe malaria in any trimester of pregnancy. 2 The maternal mortality benefit outweighs theoretical fetal risks. 2
Critical consideration: Malaria in pregnancy carries higher risk of complications, with placental sequestration causing lower peripheral parasitemia that may complicate diagnosis. 3, 2 Stillbirth, preterm delivery, and low birth weight are major risks. 4, 3
Non-Falciparum Malaria
P. vivax, P. ovale, P. malariae
Chloroquine remains the drug of choice: 600 mg base (1000 mg salt) initially, then 300 mg base at 6,24, and 48 hours (total 25 mg base/kg over 3 days). 1
Exception: For P. vivax from Papua New Guinea, Indonesia, or Sabah where chloroquine resistance exceeds 10%, use ACTs instead. 1
Alternative: ACTs (artemether-lumefantrine or dihydroartemisinin-piperaquine) are effective for all non-falciparum species and simplify treatment when species identification is uncertain. 1
Hypnozoite Eradication (P. vivax and P. ovale)
Primaquine is mandatory to prevent relapse from liver hypnozoites: 30 mg base daily for 14 days, taken concurrently with chloroquine for enhanced efficacy. 1, 2 This reduces relapse risk by 80%. 1
Critical safety requirement: Test for G6PD deficiency before primaquine administration. 2 In G6PD deficiency (30-70% activity), use 45 mg weekly for 8 weeks. 1
Absolute contraindications: Pregnancy and breastfeeding (until infant G6PD status known). 2 Use weekly chloroquine prophylaxis throughout pregnancy, then treat with primaquine postpartum. 2
Prophylaxis
All travelers to malaria-endemic regions require chemoprophylaxis. 5 Specific regimens depend on destination resistance patterns and individual contraindications. 5
Pregnant women should avoid travel to endemic areas; if unavoidable, chemoprophylaxis is essential along with insecticide-treated bed nets and mosquito bite avoidance. 3
In endemic areas, intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine is recommended, though contraindicated in HIV-infected women receiving cotrimoxazole prophylaxis. 6
Pediatric Considerations
Children with uncomplicated malaria should receive ACTs (artemether-lumefantrine or dihydroartemisinin-piperaquine) as first-line treatment at weight-based dosing. 2 Doxycycline is contraindicated under age 12 years. 2
For severe malaria in children, use intravenous artesunate plus empirical broad-spectrum antibiotics until bacterial co-infection excluded. 2